Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Base Year Market Size (2025) | USD 1.26 Billion |
| Market Size (2026) | USD 1.31 Billion |
| Market Size (2031) | USD 1.61 Billion |
| Growth Rate (2026 - 2031) | 4.20% CAGR |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Spain Diabetes Drugs Market Analysis by Mordor Intelligence
The Spain Diabetes Drugs Market size is expected to grow from USD 1.26 billion in 2025 to USD 1.31 billion in 2026 and is forecast to reach USD 1.61 billion by 2031 at 4.2% CAGR over 2026-2031.
Spain has According to WHO, 102,258,825 vaccination doses have been delivered as of June 25, 2022. Regardless of past diabetes history, entrance hyperglycemia is a significant predictor of all-cause mortality in COVID-19 patients who are not severely ill. Spain was one of the countries most hit by the COVID-19 epidemic in 2020. To contain the outbreak due to a rise in cases, a thorough national lockdown was enacted from 14 March 2020 to 21 June 2020. On October 25, the government declared a state of emergency in response to the resumption of cases following a nearly four-month period in which certain restrictive restrictions had been eased. This included partial lockdown measures with mobility restrictions, which would last until May 9, 2021. The COVID-19 pandemic in Spain has pushed the government to implement novel legislation and restrictions in an attempt to halt the virus's spread. Lockdown has been shown to be an effective approach for reducing the risk of infection. As a result of the aforementioned reasons, the expansion of the studied market in Spain is predicted.
Insulin Drugs are important components of type 1 diabetes management (T1D). Insulin drugs are examples of such drugs. These devices have been associated with improved glucose control and reduced hypoglycemia.
In terms of medicines, the insulin category commands a sizable market share. Over 100 million people worldwide use insulin, including all persons with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin production is extremely sophisticated, and there are only a few insulin manufacturers on the market. As a result, there is fierce rivalry among these producers, who are continually striving to satisfy the demands of patients by providing the highest-quality insulin.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Spain Diabetes Drugs Market Trends and Insights
Oral-Anti Diabetes Drugs is Having the Highest Market Share in the Current Year.
The oral anti-diabetic drugs segment is expected to increase with a CAGR of over 3.7% during the forecast period. Patients with type-1 diabetes (T1D) must maintain healthy lifestyle conditions, which depend on a person's personality traits, social interactions, socioeconomic circumstances, and environmental living factors. Continuous glucose monitoring (CGM) combined with multiple daily injections (MDI) has been found to reduce non-severe and severe hypoglycemia in people with T1D who are prone to this side effect. Patients with T1D at high risk of hypoglycemia could employ standalone continuous glucose monitoring to regulate their blood sugar levels, even in the terrible living conditions imposed by the COVID-19 pandemic crisis's draconian lockdown. The lockdown period was associated with a slight improvement in glucometric indicators, particularly those related to glucose exposure, which led to initiatives to lighten the load.
Although enhanced glycemic management has been recognized for decades to lower the frequency of microvascular problems, empirical information addressing macrovascular consequences and mortality has been absent until recently. Some diabetic medicines have even raised concerns about their cardiovascular safety. Furthermore, the findings of trials comparing rigorous control (HbA1c6.5%) to standard treatment in patients with DM2 and a high cardiovascular risk have called into doubt the safety of the former method, as well as glucose-lowering medication in general, in DM2.
Although enhanced glycemic management has been recognized for decades to lower the frequency of microvascular problems, empirical information addressing macrovascular consequences and mortality has been absent until recently. Some diabetic medicines have even raised concerns about their cardiovascular safety. Furthermore, the findings of trials comparing rigorous control to standard treatment in patients with DM2 and a high cardiovascular risk have called into doubt the safety of the former method, as well as glucose-lowering medication in general, in DM2.
Through the Spanish government's encouragement, the usage of management devices increased over the forecast period.
The rising prevalence of diabetes in Spain is boosting the country's diabetes device market
In Spain, the diabetes population is expected to increase by more than 2.5% over the forecast period.
According to the IDF 2021 report, diabetes prevalence in Spain reached 14.8%, or one in seven adults, the second highest rate in Europe. In addition, diabetes-related health expenditures in Spain reached 15.5 billion USD. Almost 30.3% of people living with diabetes in Spain were undiagnosed.
According to the Sociedad Espanola de Diabetes (SED), therapeutic education in diabetes has gone from being a necessity to becoming a priority and an urgency. The unstoppable increase in cases and the appearance of important developments in the control and management of the disease require, more than ever, training efforts accompanied by indispensable equity measures to facilitate the access of all people with diabetes to these new resources. The SED also recognizes the important progress made in the approach to diabetes, especially with technological advances. For example, the financing of Flash systems for people with type-2 diabetes on treatment with a bolus-basal insulin regimen has been approved.
When diabetes is undetected or inadequately treated, people with diabetes are at risk of serious and life-threatening complications, such as heart attack, stroke, kidney failure, blindness, and lower-limb amputation. These result in reduced quality of life and higher healthcare costs, leading to a greater need for access to care. Various pieces of evidence suggest that diabetes can be successfully managed, especially when detected early. Multifactorial intervention, including control of blood glucose, blood pressure, and lipids, can reduce the broad range of diabetes-related microvascular and macrovascular complications and premature mortality.
Thus, owing to the above factors, it is expected to drive market growth over the forecast period.
Competitive Landscape
The diabetes drugs market is moderately fragmented, with few significant and generic players. The insulin and Sglt-2 drug markets are dominated by a few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol-Myers Squibb. The market for oral drugs like sulfonylureas and meglitinides comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, to increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.
Spain Diabetes Drugs Industry Leaders
Eli Lilly
Boehringer Ingelheim
Astrazeneca
Sanofi
Novo Nordisk
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Spain's diabetes burden and the treatment gap around diagnosis continue to expand the addressable pool for drug therapy. IDF 2021 reports show diabetes prevalence in Spain at 14.8%, with about 30.3% of people living with diabetes undiagnosed. That combination supports earlier detection and timely initiation and intensification across oral antidiabetic drugs, insulin, and combination regimens.
Care delivery modernization and local supply capability are also shaping more consistent pathways for therapy access and follow-up. Regional initiatives, including the Valencian Community's home delivery model for glucose sensors and consumables (around 27,000 patients) and Murcia's first diabetes day hospital, point to investment in integrated, multidisciplinary management. On the manufacturing side, Spain is being used for supply readiness for metabolic medicines, with Eli Lilly preparing its Alcobendas (Madrid) plant for final production and packaging of an oral obesity treatment (orforglipron) and Novo Nordisk pursuing manufacturing partnerships, including pre-filled syringe production with Rovi. These actions, together with pricing actions on semaglutide-based medicines in early 2026 under the national health system, are relevant to how diabetes-related portfolios can scale amid affordability pressures.
Recent Industry Developments
- May 2026: Novo Nordisk announced a 77.6% increase in R&D investment in Spain for 2025, focused on obesity and cardiovascular disease research. The increase builds on Spain's role in developing next-generation diabetes and obesity therapies. It also indicates intensified local development activity.
- March 2026: Novo Nordisk announced a price reduction for semaglutide-based drugs for type 2 diabetes and obesity in Spain, effective February 1 and March 1, 2026. The pricing adjustments are designed to improve patient accessibility and reimbursement dynamics in the Spanish market. This supports wider use of GLP-1 therapies within Spain.
- February 2026: Alcobendas plant in Madrid preparing for final production and packaging of orforglipron, an oral obesity treatment. The manufacturing effort reinforces Spain as a production base for next-generation obesity and diabetes medicines. The capacity addition is intended to support supply continuity and potential regional export expansion.
Research Methodology Framework and Report Scope
Market Definition and Coverage
For this report, the market covers prescription medicines used to manage diabetes in Spain, counted as the sales value of therapies dispensed through the country's medicine supply chain in a given year.
Scope exclusions: We exclude diabetes devices (such as glucose monitors, sensors, strips, pumps, and pens) and also exclude non-drug weight management programs and non-prescription supplements.
Segmentation Overview
- Oral Anti-diabetic Drugs
- Biguanides
- Metformin
- Alpha-Glucosidase Inhibitors
- Alpha-Glucosidase Inhibitors
- Dopamine D2 receptor agonist
- Bromocriptin
- SGLT-2 inhibitors
- Invokana (Canagliflozin)
- Jardiance (Empagliflozin)
- Farxiga/Forxiga (Dapagliflozin)
- Suglat (Ipragliflozin)
- DPP-4 inhibitors
- Onglyza (Saxagliptin)
- Tradjenta (Linagliptin)
- Vipidia/Nesina(Alogliptin)
- Galvus (Vildagliptin)
- Sulfonylureas
- Sulfonylureas
- Meglitinides
- Meglitinides
- Biguanides
- Insulin Drugs
- Basal or Long Acting Insulins
- Lantus (Insulin Glargine)
- Levemir (Insulin Detemir)
- Toujeo (Insulin Glargine)
- Tresiba (Insulin Degludec)
- Basaglar (Insulin Glargine)
- Bolus or Fast Acting Insulins
- NovoRapid/Novolog (Insulin Aspart)
- Humalog (Insulin Lispro)
- Apidra (Insulin Glulisine)
- Traditional Human Insulins
- Novolin/Actrapid/Insulatard
- Humulin
- Insuman
- Biosimilar Insulins
- Insulin Glargine Biosimilars
- Human Insulin Biosimilars
- Basal or Long Acting Insulins
- Combination Drugs
- Insulin combinations
- NovoMix (Biphasic Insulin Aspart)
- Ryzodeg (Insulin Degludec and Insulin Aspart)
- Xultophy (Insulin Degludec and Liraglutide)
- Oral Combinations
- Janumet (Sitagliptin and Metformin)
- Insulin combinations
- Non-Insulin Injectable Drugs
- GLP-1 receptor agonists
- Victoza (Liraglutide)
- Byetta (Exenatide)
- Bydureon (Exenatide)
- Trulicity (Dulaglutide)
- Lyxumia (Lixisenatide)
- Amylin Analogue
- Symlin (Pramlintide)
- GLP-1 receptor agonists
Data Sources, Market Sizing, and Validation
Desk Research
Desk work starts by mapping the treated patient pool and the therapy mix that is actually used in Spain, and then linking this to pricing and reimbursement mechanics. We reference public health and medicines infrastructure sources, including Spanish Ministry of Health publications, OECD health statistics, the European Medicines Agency database, and World Health Organization guidance and indicators.
After that, we check demand and market signals that help convert epidemiology into value, and to avoid over-counting. Useful inputs include national prescription and reimbursement reporting, tender and procurement notices where relevant, peer-reviewed studies on diabetes treatment patterns, and company filings or investor presentations for product mix direction. For pricing and product availability, we also use paid subscriptions that track company financials, news and financials, and patent databases, which help us spot launch timing and life-cycle changes. These examples are not exhaustive, and additional public and paid sources were reviewed for data collection, validation, and clarification.
Primary Interviews and Surveys
Primary work focuses on confirming what is changing in actual prescribing and access, and then stress-testing model inputs that desk sources cannot fully explain. We speak with hospital and retail channel stakeholders, pharmacy and procurement experts, and clinical specialists and payor-linked viewpoints, which helps us validate class-level uptake, switching, and affordability dynamics.
To avoid over-relying on any one viewpoint, inputs are checked across different organization sizes and job roles, then reconciled back to the modeled patient pool and observed price trends.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 31% | CXOs: 13% | |
| Mid tier: 55% | Functional/Unit leaders: 38% | |
| Smaller Players: 14% | Managers: 49% |
Market-Sizing & Forecasting
The market size is built using a top-down approach where diabetes prevalence, diagnosis, and treated rates are translated into therapy demand, and then priced using Spain-relevant net price logic. We cross-check the results with selective bottom-up approximations, such as sampled class volumes times average selling prices, plus distributor and channel sense-checks, to confirm that totals do not drift away from real dispensing behavior.
Key inputs that influence the model include the share of type 2 patients on drug therapy, the split between insulin, oral agents, and non-insulin injectables, the pace of switching toward newer classes, average daily dose and adherence patterns, and reimbursement-driven price movements (including reference pricing and tender effects where applicable). When a product-level data point is missing, we fill gaps using close therapeutic substitutes, life-cycle timing, and validated class averages, then re-check the implied volumes against the treated pool.
For forecasting, we use scenario analysis supported by short trend models on the key drivers, because policy and access changes can shift class mix faster than historical growth alone would suggest. Assumptions on class penetration, therapy persistence, and pricing are refined through expert feedback before finalizing the yearly trajectory.
Data Validation & Update Cycle
Outputs are validated through multiple checks that compare the modeled value against independent signals, such as public spending direction, prescription mix changes, and known launch and loss-of-exclusivity timing. If an outlier appears, we revisit the driver chain, re-check units, and re-contact select experts when the variance cannot be explained by published information.
Before sign-off, the work goes through stepwise analyst review so that assumptions, calculations, and conversions stay consistent across years. Reports are refreshed annually, and interim updates are made when material events occur, such as major reimbursement decisions or class-level safety and label changes. Right before delivery, a final pass is completed to ensure clients receive the latest updated view.
Mordor Intelligence's Spain Diabetes Drugs Market Size Measured Against Other Published Estimates
Published market sizes for diabetes drugs in Spain can differ even when the topic sounds similar, because authors do not always measure the same thing. Differences usually come from whether the figure reflects medicine sales value or public reimbursement outlay, whether devices or broader diabetes care are included, and how net pricing and parallel channels are treated.
Some external figures describe overall diabetes spending or broader care categories and then label it as a market number. In Mordor Intelligence's estimate, only antidiabetic medicines are counted, and device spending and non-drug diabetes care are kept out, with class mix and net price assumptions checked against dispensing and access signals.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 1.26 B (2025) | |
| Trade Journal A | USD 2.70 B (2024) | This figure reflects public-funded prescription spending for diabetes medicines in Spain, which can sit above a sales-value style market estimate if it includes full reimbursed outlay, pharmacy margins, and a specific reimbursement channel focus. |
| Industry Bulletin B | USD 0.95 B (2023) | This estimate is presented as a broader diabetes market value tied to disease management and treatment rates, so the scope may blend non-drug elements or apply different net pricing and currency timing, leading to a lower medicine-only total. |
The spread in the table is mainly explained by scope and measurement choices, not by one single growth assumption. When the treated pool, class mix, and net pricing logic are kept consistent with how medicines are dispensed and paid for in Spain, the resulting market size becomes easier to trace and repeat year to year.
Key Questions Answered in the Report
How big is the Spain Diabetes Drugs Market?
The Spain Diabetes Drugs Market size is expected to reach USD 1.31 billion in 2026 and grow at a CAGR of 4.2% to reach USD 1.61 billion by 2031.
What is the current Spain Diabetes Drugs Market size?
In 2026, the Spain Diabetes Drugs Market size is expected to reach USD 1.31 billion.
Who are the key players in Spain Diabetes Drugs Market?
Eli Lilly, Boehringer Ingelheim, Astrazeneca, Sanofi and Novo Nordisk are the major companies operating in the Spain Diabetes Care Drugs Market.
What years does this Spain Diabetes Drugs Market cover, and what was the market size in 2025?
In 2025, the Spain Diabetes Drugs Market size was estimated at USD 1.26 billion. The report covers the Spain Diabetes Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023, 2024 and 2025. The report also forecasts the Spain Diabetes Drugs Market size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
